The update must include a clear explanation telling us this phase lll trial outcome means FDA approval, regardless of the screening issues. A phase lll for the sake of more data wth no chance of commercialization this go around, would be tragic...For shareholders that is.
Can anyone explain why this Plll doesn't have a name?